Search

Your search keyword '"deVos T"' showing total 254 results
Start Over Author "deVos T"
254 results on '"deVos T"'

1. A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence.

Author

Tefferi, A, Al-Ali, H, Barosi, G, Devos, T, Gisslinger, H, Jiang, Q, Kiladjian, J-J, Mesa, R, Passamonti, F, McMullin, M, Ribrag, V, Schiller, G, Vannucchi, A, Zhou, D, Reiser, D, Zhong, J, and Gale, R

Subjects
Adult, Aged, Aged, 80 and over, Biomarkers, Erythrocyte Transfusion, Female, Humans, Immunologic Factors, Male, Middle Aged, Myeloproliferative Disorders, Phenotype, Primary Myelofibrosis, Thalidomide, Treatment Outcome, Workflow
Abstract

RBC-transfusion dependence is common in persons with myeloproliferative neoplasm (MPN)-associated myelofibrosis. The objective of this study was to determine the rates of RBC-transfusion independence after therapy with pomalidomide vs placebo in persons with MPN-associated myelofibrosis and RBC-transfusion dependence. Two hundred and fifty-two subjects (intent-to-treat (ITT) population) including 229 subjects confirmed by central review (modified ITT population) were randomly assigned (2:1) to pomalidomide or placebo. Trialists and subjects were blinded to treatment allocation. Primary end point was proportion of subjects achieving RBC-transfusion independence within 6 months. One hundred and fifty-two subjects received pomalidomide and 77 placebo. Response rates were 16% (95% confidence interval (CI), 11, 23%) vs 16% (8, 26%; P=0.87). Response in the pomalidomide cohort was associated with ⩽4 U RBC/28 days (odds ratio (OR)=3.1; 0.9, 11.1), age ⩽65 (OR=2.3; 0.9, 5.5) and type of MPN-associated myelofibrosis (OR=2.6; 0.7, 9.5). Responses in the placebo cohort were associated with ⩽4 U RBC/28 days (OR=8.6; 0.9, 82.3), white blood cell at randomization >25 × 109/l (OR=4.9; 0.8, 28.9) and interval from diagnosis to randomization >2 years (OR=4.9; 1.1, 21.9). Pomalidomide was associated with increased rates of oedema and neutropenia but these adverse effects were manageable. Pomalidomide and placebo had similar RBC-transfusion-independence response rates in persons with MPN-associated RBC-transfusion dependence.

Published
2017

2. Gender Gap in Parental Leave Intentions: Evidence from 37 Countries

Author

Olsson, M.I., van Grootel, S., Block, K., Schuster, C., Meeussen, L., van Laar, C., Schmader, T., Croft, A., Shuyi Sun, M., Ainsaar, M., Aarntzen, L., Adamus, M., Anderson, J., Atkinson, C., Avicenna, M., Bąbel, P., Barth, M., Benson-Greenwald, T.M., Maloku, E., Berent, J., Bergsieker, H.B., Biernat, M., Bîrneanu, A.G., Bodinaku, B., Bosak, J., Bosson, J., Branković, M., Burkauskas, J., Čavojová, V., Cheryan, S., Choi, E., Choi, I., Contreras-Ibáñez, C.C., Coogan, A., Danyliuk, I., Dar-Nimrod, I., Dasgupta, N., de Lemus, S., Devos, T., Diab, M., Diekman, A.B., Efremova, M., Eisner, L., Eller, A., Erentaite, R., Fedáková, D., Frank, R., Gartzia, L., Gavreliuc, A., Gavreliuc, D., Gecaite-Stonciene, J., Germano, A.L., Giovannelli, I., Gismondi Diaz, R., Gitikhmayeva, L., Menkir Gizaw, A., Gjoneska, B., Martínez González, O., González, R., Grijalva, I.D., Güngör, D., Gustafsson Sendén, M., Hall, W., Harb, C., Hassan, B., Hässler, T., Hawi, D.R., Henningsen, L., Hoppe, A., Ishii, K., Jakšić, I., Jasini, A., Jurkevičienė, J., Kelmendi, K., Kirby, T.A., Kitakaji, Y., Kosakowska-Berezecka, N., Kozytska, I., Kulich, C., Kundtová-Klocová, E., Kunuroglu, F., Lapytskaia Aidy, C., Lee, A., Lindqvist, A., López-López, W., Luzvinda, L., Maricchiolo, F., Martinot, D., McNamara, R.A., Meister, A., Melka, T.L., Mickuviene, N., Miranda-Orrego, M.I., Mkamwa, T., Morandini, J., Morton, T., Mrisho, D., Nikitin, J., Otten, S., Pacilli, M.G., Page-Gould, E., Perandrés, A., Pizarro, J., Pop-Jordanova, N., Pyrkosz-Pacyna, J., Quta, S., Ramis, T.S., Rani, N., Redersdorff, S., Régner, I., Renström, E.A., Rivera-Rodriguez, A., Rocha, S.T.E., Ryabichenko, T., Saab, R., Sakata, K., Samekin, A., Sánchez-Pachecho, T., Scheifele, C., Schulmeyer, M.K., Sczesny, S., Sirlopú, D., Smith-Castro, V., Soo, K., Spaccatini, F., Steele, J.R., Steffens, M.C., Sucic, I., Vandello, J., Velásquez-Díaz, L.M., Vink, M., Vives, E., Zalalam Warkineh, T., Žeželj, I., Zhang, X., Zhao, X., Martiny, S.E., Olsson, M.I., van Grootel, S., Block, K., Schuster, C., Meeussen, L., van Laar, C., Schmader, T., Croft, A., Shuyi Sun, M., Ainsaar, M., Aarntzen, L., Adamus, M., Anderson, J., Atkinson, C., Avicenna, M., Bąbel, P., Barth, M., Benson-Greenwald, T.M., Maloku, E., Berent, J., Bergsieker, H.B., Biernat, M., Bîrneanu, A.G., Bodinaku, B., Bosak, J., Bosson, J., Branković, M., Burkauskas, J., Čavojová, V., Cheryan, S., Choi, E., Choi, I., Contreras-Ibáñez, C.C., Coogan, A., Danyliuk, I., Dar-Nimrod, I., Dasgupta, N., de Lemus, S., Devos, T., Diab, M., Diekman, A.B., Efremova, M., Eisner, L., Eller, A., Erentaite, R., Fedáková, D., Frank, R., Gartzia, L., Gavreliuc, A., Gavreliuc, D., Gecaite-Stonciene, J., Germano, A.L., Giovannelli, I., Gismondi Diaz, R., Gitikhmayeva, L., Menkir Gizaw, A., Gjoneska, B., Martínez González, O., González, R., Grijalva, I.D., Güngör, D., Gustafsson Sendén, M., Hall, W., Harb, C., Hassan, B., Hässler, T., Hawi, D.R., Henningsen, L., Hoppe, A., Ishii, K., Jakšić, I., Jasini, A., Jurkevičienė, J., Kelmendi, K., Kirby, T.A., Kitakaji, Y., Kosakowska-Berezecka, N., Kozytska, I., Kulich, C., Kundtová-Klocová, E., Kunuroglu, F., Lapytskaia Aidy, C., Lee, A., Lindqvist, A., López-López, W., Luzvinda, L., Maricchiolo, F., Martinot, D., McNamara, R.A., Meister, A., Melka, T.L., Mickuviene, N., Miranda-Orrego, M.I., Mkamwa, T., Morandini, J., Morton, T., Mrisho, D., Nikitin, J., Otten, S., Pacilli, M.G., Page-Gould, E., Perandrés, A., Pizarro, J., Pop-Jordanova, N., Pyrkosz-Pacyna, J., Quta, S., Ramis, T.S., Rani, N., Redersdorff, S., Régner, I., Renström, E.A., Rivera-Rodriguez, A., Rocha, S.T.E., Ryabichenko, T., Saab, R., Sakata, K., Samekin, A., Sánchez-Pachecho, T., Scheifele, C., Schulmeyer, M.K., Sczesny, S., Sirlopú, D., Smith-Castro, V., Soo, K., Spaccatini, F., Steele, J.R., Steffens, M.C., Sucic, I., Vandello, J., Velásquez-Díaz, L.M., Vink, M., Vives, E., Zalalam Warkineh, T., Žeželj, I., Zhang, X., Zhao, X., and Martiny, S.E.

Abstract

Despite global commitments and efforts, a gender-based division of paid and unpaid work persists. To identify how psychological factors, national policies, and the broader sociocultural context contribute to this inequality, we assessed parental-leave intentions in young adults (18–30 years old) planning to have children (N = 13,942; 8,880 identified as women; 5,062 identified as men) across 37 countries that varied in parental-leave policies and societal gender equality. In all countries, women intended to take longer leave than men. National parental-leave policies and women's political representation partially explained cross-national variations in the gender gap. Gender gaps in leave intentions were paradoxically larger in countries with more gender-egalitarian parental-leave policies (i.e., longer leave available to both fathers and mothers). Interestingly, this cross-national variation in the gender gap was driven by cross-national variations in women's (rather than men's) leave intentions. Financially generous leave and gender-egalitarian policies (linked to men's higher uptake in prior research) were not associated with leave intentions in men. Rather, men's leave intentions were related to their individual gender attitudes. Leave intentions were inversely related to career ambitions. The potential for existing policies to foster gender equality in paid and unpaid work is discussed.

Published
2023

3. Gender Gap in Parental Leave Intentions: Evidence from 37 Countries

Author

Work and Organizational Psychology: Occupational Health Psychology, Leerstoel Derks, Social-cognitive and interpersonal determinants of behaviour, Olsson, M.I., van Grootel, S., Block, K., Schuster, C., Meeussen, L., van Laar, C., Schmader, T., Croft, A., Shuyi Sun, M., Ainsaar, M., Aarntzen, L., Adamus, M., Anderson, J., Atkinson, C., Avicenna, M., Bąbel, P., Barth, M., Benson-Greenwald, T.M., Maloku, E., Berent, J., Bergsieker, H.B., Biernat, M., Bîrneanu, A.G., Bodinaku, B., Bosak, J., Bosson, J., Branković, M., Burkauskas, J., Čavojová, V., Cheryan, S., Choi, E., Choi, I., Contreras-Ibáñez, C.C., Coogan, A., Danyliuk, I., Dar-Nimrod, I., Dasgupta, N., de Lemus, S., Devos, T., Diab, M., Diekman, A.B., Efremova, M., Eisner, L., Eller, A., Erentaite, R., Fedáková, D., Frank, R., Gartzia, L., Gavreliuc, A., Gavreliuc, D., Gecaite-Stonciene, J., Germano, A.L., Giovannelli, I., Gismondi Diaz, R., Gitikhmayeva, L., Menkir Gizaw, A., Gjoneska, B., Martínez González, O., González, R., Grijalva, I.D., Güngör, D., Gustafsson Sendén, M., Hall, W., Harb, C., Hassan, B., Hässler, T., Hawi, D.R., Henningsen, L., Hoppe, A., Ishii, K., Jakšić, I., Jasini, A., Jurkevičienė, J., Kelmendi, K., Kirby, T.A., Kitakaji, Y., Kosakowska-Berezecka, N., Kozytska, I., Kulich, C., Kundtová-Klocová, E., Kunuroglu, F., Lapytskaia Aidy, C., Lee, A., Lindqvist, A., López-López, W., Luzvinda, L., Maricchiolo, F., Martinot, D., McNamara, R.A., Meister, A., Melka, T.L., Mickuviene, N., Miranda-Orrego, M.I., Mkamwa, T., Morandini, J., Morton, T., Mrisho, D., Nikitin, J., Otten, S., Pacilli, M.G., Page-Gould, E., Perandrés, A., Pizarro, J., Pop-Jordanova, N., Pyrkosz-Pacyna, J., Quta, S., Ramis, T.S., Rani, N., Redersdorff, S., Régner, I., Renström, E.A., Rivera-Rodriguez, A., Rocha, S.T.E., Ryabichenko, T., Saab, R., Sakata, K., Samekin, A., Sánchez-Pachecho, T., Scheifele, C., Schulmeyer, M.K., Sczesny, S., Sirlopú, D., Smith-Castro, V., Soo, K., Spaccatini, F., Steele, J.R., Steffens, M.C., Sucic, I., Vandello, J., Velásquez-Díaz, L.M., Vink, M., Vives, E., Zalalam Warkineh, T., Žeželj, I., Zhang, X., Zhao, X., Martiny, S.E., Work and Organizational Psychology: Occupational Health Psychology, Leerstoel Derks, Social-cognitive and interpersonal determinants of behaviour, Olsson, M.I., van Grootel, S., Block, K., Schuster, C., Meeussen, L., van Laar, C., Schmader, T., Croft, A., Shuyi Sun, M., Ainsaar, M., Aarntzen, L., Adamus, M., Anderson, J., Atkinson, C., Avicenna, M., Bąbel, P., Barth, M., Benson-Greenwald, T.M., Maloku, E., Berent, J., Bergsieker, H.B., Biernat, M., Bîrneanu, A.G., Bodinaku, B., Bosak, J., Bosson, J., Branković, M., Burkauskas, J., Čavojová, V., Cheryan, S., Choi, E., Choi, I., Contreras-Ibáñez, C.C., Coogan, A., Danyliuk, I., Dar-Nimrod, I., Dasgupta, N., de Lemus, S., Devos, T., Diab, M., Diekman, A.B., Efremova, M., Eisner, L., Eller, A., Erentaite, R., Fedáková, D., Frank, R., Gartzia, L., Gavreliuc, A., Gavreliuc, D., Gecaite-Stonciene, J., Germano, A.L., Giovannelli, I., Gismondi Diaz, R., Gitikhmayeva, L., Menkir Gizaw, A., Gjoneska, B., Martínez González, O., González, R., Grijalva, I.D., Güngör, D., Gustafsson Sendén, M., Hall, W., Harb, C., Hassan, B., Hässler, T., Hawi, D.R., Henningsen, L., Hoppe, A., Ishii, K., Jakšić, I., Jasini, A., Jurkevičienė, J., Kelmendi, K., Kirby, T.A., Kitakaji, Y., Kosakowska-Berezecka, N., Kozytska, I., Kulich, C., Kundtová-Klocová, E., Kunuroglu, F., Lapytskaia Aidy, C., Lee, A., Lindqvist, A., López-López, W., Luzvinda, L., Maricchiolo, F., Martinot, D., McNamara, R.A., Meister, A., Melka, T.L., Mickuviene, N., Miranda-Orrego, M.I., Mkamwa, T., Morandini, J., Morton, T., Mrisho, D., Nikitin, J., Otten, S., Pacilli, M.G., Page-Gould, E., Perandrés, A., Pizarro, J., Pop-Jordanova, N., Pyrkosz-Pacyna, J., Quta, S., Ramis, T.S., Rani, N., Redersdorff, S., Régner, I., Renström, E.A., Rivera-Rodriguez, A., Rocha, S.T.E., Ryabichenko, T., Saab, R., Sakata, K., Samekin, A., Sánchez-Pachecho, T., Scheifele, C., Schulmeyer, M.K., Sczesny, S., Sirlopú, D., Smith-Castro, V., Soo, K., Spaccatini, F., Steele, J.R., Steffens, M.C., Sucic, I., Vandello, J., Velásquez-Díaz, L.M., Vink, M., Vives, E., Zalalam Warkineh, T., Žeželj, I., Zhang, X., Zhao, X., and Martiny, S.E.

Published
2023

4. A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis

Author

Passamonti, F, Giorgino, T, Mora, B, Guglielmelli, P, Rumi, E, Maffioli, M, Rambaldi, A, Caramella, M, Komrokji, R, Gotlib, J, Kiladjian, J J, Cervantes, F, Devos, T, Palandri, F, De Stefano, V, Ruggeri, M, Silver, R T, Benevolo, G, Albano, F, Caramazza, D, Merli, M, Pietra, D, Casalone, R, Rotunno, G, Barbui, T, Cazzola, M, and Vannucchi, A M

Published
2017
Full Text
View/download PDF

5. Driver mutations’ effect in secondary myelofibrosis: an international multicenter study based on 781 patients

Author

Passamonti, F, Mora, B, Giorgino, T, Guglielmelli, P, Cazzola, M, Maffioli, M, Rambaldi, A, Caramella, M, Komrokji, R, Gotlib, J, Kiladjian, J J, Cervantes, F, Devos, T, Palandri, F, De Stefano, V, Ruggeri, M, Silver, R, Benevolo, G, Albano, F, Caramazza, D, Rumi, E, Merli, M, Pietra, D, Casalone, R, Barbui, T, Pieri, L, and Vannucchi, A M

Published
2017
Full Text
View/download PDF

6. P699: REAL-LIFE OUTCOMES OF PONATINIB TREATMENT IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML) OR PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ALL): 5-YEAR-DATA FROM A BELGIAN REGISTRY

Author

Devos, T., primary, Havelange, V., additional, Theunissen, K., additional, Meers, S., additional, Benghiat, F. S., additional, Gadisseur, A., additional, Vanstraelen, G., additional, Vellemans, H., additional, Bailly, B., additional, Granacher, N., additional, Lewalle, P., additional, De Becker, A., additional, Van Eygen, K., additional, Lejeune, M., additional, Janssen, M., additional, Triffet, A., additional, Vrelust, I., additional, Deeren, D., additional, Mazure, D., additional, Beck, M., additional, Sebti, H., additional, and Selleslag, D., additional

Published
2022
Full Text
View/download PDF

7. S198: BET INHIBITOR PELABRESIB (CPI-0610) COMBINED WITH RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS — JAK INHIBITOR-NAÏVE OR WITH SUBOPTIMAL RESPONSE TO RUXOLITINIB — PRELIMINARY DATA FROM THE MANIFEST STUDY

Author

Mascarenhas, J., primary, Kremyanskaya, M., additional, Patriarca, A., additional, Harrison, C., additional, Bose, P., additional, Rampal, R. K., additional, Palandri, F, additional, Devos, T., additional, Passamonti, F., additional, Hobbs, G., additional, Talpaz, M., additional, Vannucchi, A., additional, Kiladjian, J.-J., additional, Verstovsek, S., additional, Hoffman, R., additional, Salama, M. E., additional, Chen, D., additional, Taverna, P., additional, Chang, A., additional, Colak, G., additional, Klein, S., additional, and Gupta, V., additional

Published
2022
Full Text
View/download PDF

8. P995: MYELOID NEOPLASMS-ASSOCIATED GENE VARIANTS IN 639 PATIENTS WITH POST-POLYCYTHEMIA VERA AND POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS: AN ANALYSIS OF THE MYSEC COHORT

Author

Mora, B., primary, Guglielmelli, P., additional, Kuykendall, A., additional, Maffioli, M., additional, Rotunno, G., additional, Komrokji, R. S., additional, Palandri, F., additional, Kiladjian, J.-J., additional, Iurlo, A., additional, Auteri, G., additional, Cattaneo, D., additional, De Stefano, V., additional, Salmoiraghi, S., additional, Devos, T., additional, Cervantes, F., additional, Merli, M., additional, Campagna, A., additional, Benevolo, G., additional, Brociner, M., additional, Albano, F., additional, Gotlib, J., additional, Caramella, M., additional, Ruggeri, M., additional, Ross, D. M., additional, Orsini, F., additional, Pessina, C., additional, Colugnat, I., additional, Pallotti, F., additional, Barbui, T., additional, Bertù, L., additional, Della Porta, M. G., additional, Vannucchi, A. M., additional, and Passamonti, F., additional

Published
2022
Full Text
View/download PDF

9. P1041: IMPACT OF FEDRATINIB ON SPLEEN VOLUME AND MYELOFIBROSIS SYMPTOMS IN PATIENTS WITH SUBSTANTIAL SPLENOMEGALY: POST HOC ANALYSES FROM THE JAKARTA AND JAKARTA2 TRIALS

Author

Kiladjian, J.-J., primary, Tefferi, A., additional, Passamonti, F., additional, Vannucchi, A., additional, Talpaz, M., additional, Cervantes, F., additional, Harrison, C. N., additional, Mesa, R. A., additional, Mascarenhas, J., additional, Schaap, N., additional, Verstovsek, S., additional, Devos, T., additional, Rose, S., additional, Zhang, J., additional, Sy, O., additional, and Pardanani, A., additional

Published
2022
Full Text
View/download PDF

10. P1030: MANIFEST-2, A GLOBAL, PHASE 3, RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROL STUDY OF PELABRESIB (CPI-0610) AND RUXOLITINIB VS PLACEBO AND RUXOLITINIB IN JAK INHIBITOR-NAÏVE MYELOFIBROSIS PATIENTS

Author

Harrison, C., primary, Rampal, R. K., additional, Gupta, V., additional, Verstovsek, S., additional, Talpaz, M., additional, Kiladjian, J.-J., additional, Mesa, R., additional, Kuykendall, A., additional, Vannucchi, A., additional, Palandri, F., additional, Grosicki, S., additional, Devos, T., additional, Jourdan, E., additional, Wondergem, M. J., additional, Al-Ali, H. K., additional, Buxhofer-Ausch, V., additional, Alvarez-Larrán, A., additional, Akhani, S., additional, Muñoz-Carerras, R., additional, Sheykin, Y., additional, Colak, G., additional, Harris, M., additional, and Mascarenhas, J., additional

Published
2022
Full Text
View/download PDF

11. P1361: TREATMENT OF SEVERE STEROID-REFRACTORY ACUTE GVHD WITH MESENCHYMAL STROMAL CELLS: RESULTS OF THE PHASE III RANDOMIZED DOUBLE-BLIND MULTI-CENTER HOVON-113 TRIAL

Author

Oosten, L., primary, van Pel, M., additional, van der Holt, B., additional, Bach, E., additional, Cross, M., additional, Roelofs, H., additional, Meij, P., additional, Wieles, B., additional, Zwaginga, J. J., additional, Lankester, A., additional, Veelken, H., additional, Platzbecker, U., additional, Sanchez-Guijo, F., additional, Algeri, M., additional, Locatelli, F., additional, Devos, T., additional, Cornelissen, J., additional, Niederwieser, D., additional, and Fibbe, W., additional

Published
2022
Full Text
View/download PDF

19. Impact of bone marrow fibrosis grade in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A study of the MYSEC group

Author

Mora, B., Guglielmelli, P., Rumi, E., Maffioli, M., Barraco, D., Rambaldi, A., Caramella, M., Komrokji, R. S., Kiladjian, J. -J., Gotlib, J., Iurlo, A., Cervantes, F., Devos, T., Palandri, F., De Stefano, Valerio, Ruggeri, M., Silver, R. T., Albano, F., Benevolo, G., Cavalloni, C., Uccella, S., Accetta, R., Siracusa, C., Agnoli, S., Merli, M., Barbui, T., Bertu, L., Cazzola, M., Vannucchi, A. M., Passamonti, F., De Stefano V. (ORCID:0000-0002-5178-5827), Mora, B., Guglielmelli, P., Rumi, E., Maffioli, M., Barraco, D., Rambaldi, A., Caramella, M., Komrokji, R. S., Kiladjian, J. -J., Gotlib, J., Iurlo, A., Cervantes, F., Devos, T., Palandri, F., De Stefano, Valerio, Ruggeri, M., Silver, R. T., Albano, F., Benevolo, G., Cavalloni, C., Uccella, S., Accetta, R., Siracusa, C., Agnoli, S., Merli, M., Barbui, T., Bertu, L., Cazzola, M., Vannucchi, A. M., Passamonti, F., and De Stefano V. (ORCID:0000-0002-5178-5827)

Abstract

N/A

Published
2020

22. PS1458 RISK FACTORS AND OUTCOME OF ACUTE MYELOID LEUKEMIA SECONDARY TO POST-POLYCYTHEMIA VERA AND POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS: AN ANALYSIS OF THE MYSEC COHORT

Author

Mora, B., primary, Guglielmelli, P., additional, Rumi, E., additional, Maffioli, M., additional, Barraco, D., additional, Rambaldi, A., additional, Caramella, M., additional, Komrokji, R., additional, Kiladjian, J.J., additional, Gotlib, J., additional, Iurlo, A., additional, Cervantes, F., additional, Devos, T., additional, Palandri, F., additional, De Stefano, V., additional, Ruggeri, M., additional, Silver, R.T., additional, Benevolo, G., additional, Albano, F., additional, Cavalloni, C., additional, Pietra, D., additional, Barbui, T., additional, Rotunno, G., additional, Bertù, L., additional, Cazzola, M., additional, Vannucchi, A.M., additional, and Passamonti, F., additional

Published
2019
Full Text
View/download PDF

24. Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients

Author

Mora, B., Rumi, E., Guglielmelli, P., Barraco, D., Maffioli, M., Rambaldi, A., Caramella, M., Komrokji, R., Gotlib, J., Kiladjian, J. J., Cervantes, F., Devos, T., Palandri, F., De Stefano, Valerio, Ruggeri, M., Silver, R. T., Benevolo, G., Albano, F., Cavalloni, C., Pietra, D., Barbui, T., Rotunno, G., Cazzola, M., Vannucchi, A. M., Giorgino, T., Passamonti, F., De Stefano V. (ORCID:0000-0002-5178-5827), Mora, B., Rumi, E., Guglielmelli, P., Barraco, D., Maffioli, M., Rambaldi, A., Caramella, M., Komrokji, R., Gotlib, J., Kiladjian, J. J., Cervantes, F., Devos, T., Palandri, F., De Stefano, Valerio, Ruggeri, M., Silver, R. T., Benevolo, G., Albano, F., Cavalloni, C., Pietra, D., Barbui, T., Rotunno, G., Cazzola, M., Vannucchi, A. M., Giorgino, T., Passamonti, F., and De Stefano V. (ORCID:0000-0002-5178-5827)

Abstract

Patients with myeloproliferative neoplasms (MPN) are known to have higher incidence of nonhematological second primary malignancies (SPM) compared to general population. In the MYSEC study on 781 secondary myelofibrosis (SMF) patients, the incidence of SPM after SMF diagnosis resulted 0.98/100 patient-years. When including non-melanoma skin cancers (NMSC), the incidence arose to 1.56/100 patientyears. In SMF, JAK inhibitor treatment was associated only with NMSC occurrence. Then, we merged the MYSEC cohort with a large dataset of PV and ET not evolving into SMF. In this subanalysis, we did not find any correlation between SPM and SMF occurrence. These findings highlight the need of studies aimed at identifying MPN patients at higher risk of SPM.

Published
2019

26. Diagnosis and management of PNH: review and recommendations from a Belgian expert panel.

Author

UCL - (MGD) Service d'hématologie, UCL - (MGD) Laboratoire de biologie clinique, UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - SSS/IREC/MONT - Pôle Mont Godinne, Devos, T, Meers, S, Boeckx, N, Gothot, A, Deeren, D, Chatelain, Bernard, Chatelain, Christian, Devalet, Bérangère, UCL - (MGD) Service d'hématologie, UCL - (MGD) Laboratoire de biologie clinique, UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - SSS/IREC/MONT - Pôle Mont Godinne, Devos, T, Meers, S, Boeckx, N, Gothot, A, Deeren, D, Chatelain, Bernard, Chatelain, Christian, and Devalet, Bérangère

Abstract

Despite its considerable morbidity and mortality, paroxysmal nocturnal haemoglobinuria (PNH) is still underdiagnosed. Patients with PNH can suffer from cardiovascular, gastro-intestinal, neurological or haematological symptoms and refer to several specialists. The aim of this paper is to review the diagnosis and the management of PNH patients, with the primary focus on identifying high-risk groups. Additionally, the implementation and prognostic value of the defined high-risk groups will be commented on and the management of PNH patients is discussed from a Belgian perspective. Finally, based on the available data, recommendations are provided. Eculizumab is a potent C5 complement inhibitor and reduces intravascular haemolysis and thrombosis in PNH patients and improves their quality of life. As thrombosis is the main cause of death in PNH patients, identifying high-risk PNH patients in need of therapy is essential. Currently, novel complement inhibitors are in development and the first data seem promising. Another challenge in PNH is to identify new markers to assess the thrombotic risk to achieve a better risk-based prophylactic anti-thrombotic management. Finally, because of the low prevalence of the disease, PNH patients should be included in the prospective PNH registry, which will offer new insights on the natural course of the disease and the impact of treatment of PNH. This article is protected by copyright. All rights reserved.

Published
2018

27. Many labs 2: Investigating variation in replicability across samples and settings

Author

Klein, RA, Vianello, M, Hasselman, F, Adams, BG, Adams, RB, Alper, S, Aveyard, M, Axt, JR, Babalola, MT, Bahník, Š, Batra, R, Berkics, M, Bernstein, MJ, Berry, DR, Bialobrzeska, O, Binan, ED, Bocian, K, Brandt, MJ, Busching, R, Rédei, AC, Cai, H, Cambier, F, Cantarero, K, Carmichael, CL, Ceric, F, Chandler, J, Chang, JH, Chatard, A, Chen, EE, Cheong, W, Cicero, DC, Coen, S, Coleman, JA, Collisson, B, Conway, MA, Corker, KS, Curran, PG, Cushman, F, Dagona, ZK, Dalgar, I, Dalla Rosa, A, Davis, WE, de Bruijn, M, De Schutter, L, Devos, T, de Vries, M, Doğulu, C, Dozo, N, Dukes, KN, Dunham, Y, Durrheim, K, Ebersole, CR, Edlund, JE, Eller, A, English, AS, Finck, C, Frankowska, N, Freyre, MÁ, Friedman, M, Galliani, EM, Gandi, JC, Ghoshal, T, Giessner, SR, Gill, T, Gnambs, T, Gómez, Á, González, R, Graham, J, Grahe, JE, Grahek, I, Green, EGT, Hai, K, Haigh, M, Haines, EL, Hall, MP, Heffernan, ME, Hicks, JA, Houdek, P, Huntsinger, JR, Huynh, HP, Ijzerman, H, Inbar, Y, Innes-Ker, ÅH, Jiménez-Leal, W, John, MS, Joy-Gaba, JA, Kamiloğlu, RG, Kappes, HB, Karabati, S, Karick, H, Keller, VN, Kende, A, Kervyn, N, Knežević, G, Kovacs, C, Krueger, LE, Kurapov, G, Kurtz, J, Lakens, D, Lazarević, LB, Klein, RA, Vianello, M, Hasselman, F, Adams, BG, Adams, RB, Alper, S, Aveyard, M, Axt, JR, Babalola, MT, Bahník, Š, Batra, R, Berkics, M, Bernstein, MJ, Berry, DR, Bialobrzeska, O, Binan, ED, Bocian, K, Brandt, MJ, Busching, R, Rédei, AC, Cai, H, Cambier, F, Cantarero, K, Carmichael, CL, Ceric, F, Chandler, J, Chang, JH, Chatard, A, Chen, EE, Cheong, W, Cicero, DC, Coen, S, Coleman, JA, Collisson, B, Conway, MA, Corker, KS, Curran, PG, Cushman, F, Dagona, ZK, Dalgar, I, Dalla Rosa, A, Davis, WE, de Bruijn, M, De Schutter, L, Devos, T, de Vries, M, Doğulu, C, Dozo, N, Dukes, KN, Dunham, Y, Durrheim, K, Ebersole, CR, Edlund, JE, Eller, A, English, AS, Finck, C, Frankowska, N, Freyre, MÁ, Friedman, M, Galliani, EM, Gandi, JC, Ghoshal, T, Giessner, SR, Gill, T, Gnambs, T, Gómez, Á, González, R, Graham, J, Grahe, JE, Grahek, I, Green, EGT, Hai, K, Haigh, M, Haines, EL, Hall, MP, Heffernan, ME, Hicks, JA, Houdek, P, Huntsinger, JR, Huynh, HP, Ijzerman, H, Inbar, Y, Innes-Ker, ÅH, Jiménez-Leal, W, John, MS, Joy-Gaba, JA, Kamiloğlu, RG, Kappes, HB, Karabati, S, Karick, H, Keller, VN, Kende, A, Kervyn, N, Knežević, G, Kovacs, C, Krueger, LE, Kurapov, G, Kurtz, J, Lakens, D, and Lazarević, LB

Abstract

We conducted preregistered replications of 28 classic and contemporary published findings, with protocols that were peer reviewed in advance, to examine variation in effect magnitudes across samples and settings. Each protocol was administered to approximately half of 125 samples that comprised 15,305 participants from 36 countries and territories. Using the conventional criterion of statistical significance (p <.05), we found that 15 (54%) of the replications provided evidence of a statistically significant effect in the same direction as the original finding. With a strict significance criterion (p <.0001), 14 (50%) of the replications still provided such evidence, a reflection of the extremely highpowered design. Seven (25%) of the replications yielded effect sizes larger than the original ones, and 21 (75%) yielded effect sizes smaller than the original ones. The median comparable Cohen’s ds were 0.60 for the original findings and 0.15 for the replications. The effect sizes were small (< 0.20) in 16 of the replications (57%), and 9 effects (32%) were in the direction opposite the direction of the original effect. Across settings, the Q statistic indicated significant heterogeneity in 11 (39%) of the replication effects, and most of those were among the findings with the largest overall effect sizes; only 1 effect that was near zero in the aggregate showed significant heterogeneity according to this measure. Only 1 effect had a tau value greater than.20, an indication of moderate heterogeneity. Eight others had tau values near or slightly above.10, an indication of slight heterogeneity. Moderation tests indicated that very little heterogeneity was attributable to the order in which the tasks were performed or whether the tasks were administered in lab versus online. Exploratory comparisons revealed little heterogeneity between Western, educated, industrialized, rich, and democratic (WEIRD) cultures and less WEIRD cultures (i.e., cultures with relatively high and

Published
2018

28. Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project

Author

Barraco, D., Mora, B., Guglielmelli, P., Rumi, E., Maffioli, M., Rambaldi, A., Caramella, M., Komrokji, R., Gotlib, J., Kiladjian, J. J., Cervantes, F., Devos, T., Palandri, F., De Stefano, V., Ruggeri, M., Silver, R. T., Benevolo, G., Albano, F., Merli, M., Pietra, D., Barbui, T., Rotunno, G., Cazzola, M., Giorgino, T., Vannucchi, A. M., Passamonti, F., De Stefano V. (ORCID:0000-0002-5178-5827), Barraco, D., Mora, B., Guglielmelli, P., Rumi, E., Maffioli, M., Rambaldi, A., Caramella, M., Komrokji, R., Gotlib, J., Kiladjian, J. J., Cervantes, F., Devos, T., Palandri, F., De Stefano, V., Ruggeri, M., Silver, R. T., Benevolo, G., Albano, F., Merli, M., Pietra, D., Barbui, T., Rotunno, G., Cazzola, M., Giorgino, T., Vannucchi, A. M., Passamonti, F., and De Stefano V. (ORCID:0000-0002-5178-5827)

Abstract

N/A

Published
2018

29. Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A study of the MYSEC project

Author

Mora, B., Giorgino, T., Guglielmelli, P., Rumi, E., Maffioli, M., Rambaldi, A., Caramella, M., Komrokji, R., Gotlib, J., Kiladjian, J. J., Cervantes, F., Devos, T., Palandri, F., De Stefano, Valerio, Ruggeri, M., Silver, R. T., Benevolo, G., Albano, F., Cavalloni, C., Barraco, D., Merli, M., Pietra, D., Casalone, R., Barbui, T., Rotunno, G., Cazzola, M., Vannucchi, A. M., Passamonti, F., De Stefano V. (ORCID:0000-0002-5178-5827), Mora, B., Giorgino, T., Guglielmelli, P., Rumi, E., Maffioli, M., Rambaldi, A., Caramella, M., Komrokji, R., Gotlib, J., Kiladjian, J. J., Cervantes, F., Devos, T., Palandri, F., De Stefano, Valerio, Ruggeri, M., Silver, R. T., Benevolo, G., Albano, F., Cavalloni, C., Barraco, D., Merli, M., Pietra, D., Casalone, R., Barbui, T., Rotunno, G., Cazzola, M., Vannucchi, A. M., Passamonti, F., and De Stefano V. (ORCID:0000-0002-5178-5827)

Abstract

N/A

Published
2018

30. Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia

Author

Mora, B., Giorgino, T., Guglielmelli, P., Rumi, E., Maffioli, M., Rambaldi, A., Caramella, M., Komrokji, R., Gotlib, J., Kiladjian, J. J., Cervantes, F., Devos, T., Palandri, F., De Stefano, Valerio, Ruggeri, M., Silver, R. T., Benevolo, G., Albano, F., Cavalloni, C., Barraco, D., Pietra, D., Barbui, T., Rotunno, G., Vannucchi, A. M., Passamonti, F., De Stefano V. (ORCID:0000-0002-5178-5827), Mora, B., Giorgino, T., Guglielmelli, P., Rumi, E., Maffioli, M., Rambaldi, A., Caramella, M., Komrokji, R., Gotlib, J., Kiladjian, J. J., Cervantes, F., Devos, T., Palandri, F., De Stefano, Valerio, Ruggeri, M., Silver, R. T., Benevolo, G., Albano, F., Cavalloni, C., Barraco, D., Pietra, D., Barbui, T., Rotunno, G., Vannucchi, A. M., Passamonti, F., and De Stefano V. (ORCID:0000-0002-5178-5827)

Abstract

N/A

Published
2018

32. Human Values and Trust in Institutions across Countries: A Multilevel Test of Schwartz's Hypothesis of Structural Equivalence

Author

Davide Morselli, Spini, D., and Devos, T.

Subjects
Vertrauen, Wert, multilevel structural equation modelling, Institution, value-orientation, Wertorientierung, Sociology & anthropology, Wertsystem, value, Soziologie, Anthropologie, Allgemeine Soziologie, Makrosoziologie, spezielle Theorien und Schulen, Entwicklung und Geschichte der Soziologie, value analysis, values, soziale Norm, lcsh:H1-99, General Sociology, Basic Research, General Concepts and History of Sociology, Sociological Theories, ddc:301, confidence, lcsh:Social sciences (General), trust in institutions, social norm, World Values Survey, value system, Wertanalyse
Abstract

The goal of this article was to show how structural equation modelling associated to multilevel regressions represents a powerful tool to examine innovative cross-cultural research questions. The relationship between values and trust in institutions was investigated in four cross-cultural datasets: three were students and teacher samples; the last was a general sample from the 2005 World Values Survey (WVS). The hypothesis of equivalence of the structure of relations between values and trust in institutions (sinusoid curve hypothesis) was tested with a series of multilevel multiple indicators and multiple causes models with random slopes. Structural equivalence was confirmed for student samples, but not for the general sample. The between-country variance of the relationship between values and trust in the general sample was partially explained by country level differences in socio-economic wealth and quality of governance., Survey Research Methods, Vol 6, No 1 (2012): Special Issue on the Theory of Human Values

Published
2012

33. A novel approach for BCR-ABL1 standardization to improve International Scale estimation

Author

Maes, B, Bakkus, M, Boeckx, N, Boone, E, Cauwelier, B, Denys, B, De Schouwer, P, Devos, T, El Housni, H, Hillen, F, Jacobs, K, Lambert, F, Louagie, H, Maes, M-B, Meeus, P, Moreau, E, Nollet, F, Peeters, K, Saussoy, P, Van Lint, P, Vaerman, J-L, Vaeyens, F, Vandepoele, K, Vannuffel, P, Ver Elst, K, Vermeulen, K, Bruyndonckx, R, Belgian working group on BCR-ABL1 IS standardization, Amsterdam Movement Sciences, Rehabilitation medicine, Hematology, and Belgian Working Grp BCR-ABL1 IS St

Subjects
Standardization, Process (engineering), International scale, Clinical Biochemistry, Fusion Proteins, bcr-abl, methods, 03 medical and health sciences, Bcr abl1, 0302 clinical medicine, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, hemic and lymphatic diseases, External quality assessment, Medicine, Genetic Testing, RNA, Messenger, Retrospective Studies, Estimation, Observer Variation, SIMPLE (military communications protocol), business.industry, international cooperation, Biochemistry (medical), Conversion factor, Hematology, General Medicine, Reference Standards, chronic myelogenous leukaemia, BCR-ABL1, standardization, international scale, therapymonitoring, Reliability engineering, 030220 oncology & carcinogenesis, Human medicine, business, 030215 immunology
Abstract

Introduction: Standardization of BCR-ABL1 messenger RNA quantifi-cation by real-time PCR on the International Scale (IS) is critical for monitoring therapy response in chronic myelogenous leukaemia. Since 2006, BCR-ABL1 IS standardization is propagated along reference laboratories by calculating a laboratory-specific conversion factor (CF), co-ordinated in Europe through the European Treatment and Outcome Study project. Although this process has proven successful to some extent, it has not been achievable for all laboratories due to the complexity of the process and the stringent requirements in terms of numbers of samples to be exchanged. In addition, several BCR-ABL1 IS quantification methods and secondary reference materials became commercially available. However, it was observed that different IS methods generate consistently different results. Methods: To overcome these difficulties, we have developed an alternative and simple approach of CF calculation, based on the retrospective analysis of existing external quality assessment (EQA)data. Our approach does not depend on the exchange of samples and is solely based on the mathematical CF calculation using EQA results.R esults and conclusion: We have demonstrated by thorough statistical validation that this approach performs well in converting BCR-ABL1 measurements to improve IS estimation. In expectation of a true golden standard method for BCR-ABL1 IS quantification, the pro-posed method is a valuable alternative. We thank all the members of the Belgian workinggroup on BCR-ABL1 standardization for sharing theEQA data. We are grateful to Prof. David Barnett andMr Stuart Scott for reviewing the manuscript and forallowing us to use and interpret UKNEQAS LI data aswe feel appropriate. This work was supported byNovartis Pharma.

Published
2016

35. Prospective Evaluation of WHO and European Clinical, Molecular and Pathological (WHO-ECMP) Criteria for Myeloproliferative Neoplasms (MPN) of Various Molecular Etiology: Characteristics of JAK2V617F, MPL515 and CALR Mutated MPN

Author

Devos T, Hendrik De Raeve, Potters, Fostier K, Fransje Valster, Michiels Jj, and Schelfout K

Subjects
Oncology, Pathology, medicine.medical_specialty, Essential thrombocythemia, business.industry, Jak2 mutation, medicine.disease, Prospective evaluation, Polycythemia vera, Internal medicine, medicine, Etiology, Myelofibrosis, business, Pathological
Published
2015
Full Text
View/download PDF

36. Dossier Arbeidsveiligheid eerst, altijd en overal

Author

Van Bavel, J., De Sutter, R., Goegebeur, F., Jolling, L., Van Damme, V., Devos, T., Kint, S., Delbeke, P.-J., Van Bavel, J., De Sutter, R., Goegebeur, F., Jolling, L., Van Damme, V., Devos, T., Kint, S., and Delbeke, P.-J.

Abstract

‘Veiligheid komt niet per ongeluk’ lees je op de website van preventiedienst Prevent Agri. Aan arbeidsveiligheid moet je elke dag werken en vooral, goed bewust zijn dat een ongeval ook jou of een medewerker kan overkomen. In dit dossier mogelijke risico’s in diverse sectoren, zoals elektrische installaties, mestgassen en stof (veehouderij), bewegende onderdelen van machines, gewasbeschermingsmiddelen en brandveiligheid (groenteteelt) en ULO-koelcellen (fruitteelt) belicht. Je krijgt ook tips om de arbeidsveiligheid op je bedrijf te verhogen. Tot slot informatie over Prevent Agri en externe dienst Idewe hoe zij hun dienstverlening naar de land- en tuinbouwers optimaliseren.

Published
2017

37. Driver mutations' effect in secondary myelofibrosis: An international multicenter study based on 781 patients

Author

Passamonti, F., Mora, B., Giorgino, T., Guglielmelli, P., Cazzola, M., Maffioli, M., Rambaldi, A., Caramella, M., Komrokji, R., Gotlib, J., Kiladjian, J. J., Cervantes, F., Devos, T., Palandri, F., De Stefano, V., Ruggeri, M., Silver, R., Benevolo, G., Albano, F., Caramazza, D., Rumi, E., Merli, M., Pietra, D., Casalone, R., Barbui, T., Pieri, L., Vannucchi, A. M., De Stefano, V. (ORCID:0000-0002-5178-5827), Passamonti, F., Mora, B., Giorgino, T., Guglielmelli, P., Cazzola, M., Maffioli, M., Rambaldi, A., Caramella, M., Komrokji, R., Gotlib, J., Kiladjian, J. J., Cervantes, F., Devos, T., Palandri, F., De Stefano, V., Ruggeri, M., Silver, R., Benevolo, G., Albano, F., Caramazza, D., Rumi, E., Merli, M., Pietra, D., Casalone, R., Barbui, T., Pieri, L., Vannucchi, A. M., and De Stefano, V. (ORCID:0000-0002-5178-5827)

Abstract

N/A

Published
2017

38. A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis

Author

Passamonti, F., Giorgino, T., Mora, B., Guglielmelli, P., Rumi, E., Maffioli, M., Rambaldi, A., Caramella, M., Komrokji, R., Gotlib, J., Kiladjian, J. J., Cervantes, F., Devos, T., Palandri, F., De Stefano, Valerio, Ruggeri, M., Silver, R. T., Benevolo, G., Albano, F., Caramazza, D., Merli, M., Pietra, D., Casalone, R., Rotunno, G., Barbui, T., Cazzola, M., Vannucchi, A. M., De Stefano, V. (ORCID:0000-0002-5178-5827), Passamonti, F., Giorgino, T., Mora, B., Guglielmelli, P., Rumi, E., Maffioli, M., Rambaldi, A., Caramella, M., Komrokji, R., Gotlib, J., Kiladjian, J. J., Cervantes, F., Devos, T., Palandri, F., De Stefano, Valerio, Ruggeri, M., Silver, R. T., Benevolo, G., Albano, F., Caramazza, D., Merli, M., Pietra, D., Casalone, R., Rotunno, G., Barbui, T., Cazzola, M., Vannucchi, A. M., and De Stefano, V. (ORCID:0000-0002-5178-5827)

Abstract

Polycythemia vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms with variable risk of evolution into post-PV and post-ET myelofibrosis, from now on referred to as secondary myelofibrosis (SMF). No specific tools have been defined for risk stratification in SMF. To develop a prognostic model for predicting survival, we studied 685 JAK2, CALR, and MPL annotated patients with SMF. Median survival of the whole cohort was 9.3 years (95% CI: 8-not reached-NR-). Through penalized Cox regressions we identified negative predictors of survival and according to beta risk coefficients we assigned 2 points to hemoglobin level o 11 g/dl, to circulating blasts 3%, and to CALR-unmutated genotype, 1 point to platelet count o 150 × 109/l and to constitutional symptoms, and 0.15 points to any year of age. Myelofibrosis Secondary to PV and ET-Prognostic Model (MYSEC-PM) allocated SMF patients into four risk categories with different survival (P o 0.0001): low (median survival NR; 133 patients), intermediate-1 (9.3 years, 95% CI: 8.1-NR; 245 patients), intermediate-2 (4.4 years, 95% CI: 3.2–7.9; 126 patients), and high risk (2 years, 95% CI: 1.7–3.9; 75 patients). Finally, we found that the MYSEC-PM represents the most appropriate tool for SMF decision-making to be used in clinical and trial settings.

Published
2017

41. Discontinuation of imatinib in Belgian patients with chronic myeloid leukaemia

Author

UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - (MGD) Service d'hématologie, UCL - SSS/IREC/MONT - Pôle Mont Godinne, Mineur, P, Doyen, Chantal, Straetemans, N, Van Eygen, K, Pranger, D, Bosly, André, André, Marc, Devos, T, Knoops, L, UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - (MGD) Service d'hématologie, UCL - SSS/IREC/MONT - Pôle Mont Godinne, Mineur, P, Doyen, Chantal, Straetemans, N, Van Eygen, K, Pranger, D, Bosly, André, André, Marc, Devos, T, and Knoops, L

Published
2016

42. A novel approach for BCR-ABL1 standardization to improve International Scale estimation

Author

UCL - SSS/IREC/SLUC - Pôle St.-Luc, UCL - (SLuc) Centre de thérapie tissulaire et cellulaire, UCL - (SLuc) Service de biologie hématologique, Maes, B, Bakkus, M, Boeckx, N, Boone, E, Cauwelier, B, Denys, B, De Schouwer, P, Devos, T, El Housni, H, Hillen, F, Jacobs, K, Lambert, F, Louagie, H, Maes, M-B, Meeus, P, Moreau, E, Nollet, F, Peeters, K, Saussoy, Pascale, Van Lint, P, Vaerman, Jean-Luc, Vaeyens, F, Vandepoele, K, Vannuffel, P, Ver Elst, K, Vermeulen, K, Bruyndonckx, R, Belgian working group on BCR-ABL1 IS standardization, UCL - SSS/IREC/SLUC - Pôle St.-Luc, UCL - (SLuc) Centre de thérapie tissulaire et cellulaire, UCL - (SLuc) Service de biologie hématologique, Maes, B, Bakkus, M, Boeckx, N, Boone, E, Cauwelier, B, Denys, B, De Schouwer, P, Devos, T, El Housni, H, Hillen, F, Jacobs, K, Lambert, F, Louagie, H, Maes, M-B, Meeus, P, Moreau, E, Nollet, F, Peeters, K, Saussoy, Pascale, Van Lint, P, Vaerman, Jean-Luc, Vaeyens, F, Vandepoele, K, Vannuffel, P, Ver Elst, K, Vermeulen, K, Bruyndonckx, R, and Belgian working group on BCR-ABL1 IS standardization

Abstract

INTRODUCTION: Standardization of BCR-ABL1 messenger RNA quantification by real-time PCR on the International Scale (IS) is critical for monitoring therapy response in chronic myelogenous leukaemia. Since 2006, BCR-ABL1 IS standardization is propagated along reference laboratories by calculating a laboratory-specific conversion factor (CF), co-ordinated in Europe through the European Treatment and Outcome Study project. Although this process has proven successful to some extent, it has not been achievable for all laboratories due to the complexity of the process and the stringent requirements in terms of numbers of samples to be exchanged. In addition, several BCR-ABL1 IS quantification methods and secondary reference materials became commercially available. However, it was observed that different IS methods generate consistently different results. METHODS: To overcome these difficulties, we have developed an alternative and simple approach of CF calculation, based on the retrospective analysis of existing external quality assessment (EQA) data. Our approach does not depend on the exchange of samples and is solely based on the mathematical CF calculation using EQA results. RESULTS AND CONCLUSION: We have demonstrated by thorough statistical validation that this approach performs well in converting BCR-ABL1 measurements to improve IS estimation. In expectation of a true golden standard method for BCR-ABL1 IS quantification, the proposed method is a valuable alternative.

Published
2016

43. Driver mutations’ effect in secondary myelofibrosis: an international multicenter study based on 781 patients

Author

Passamonti, F, primary, Mora, B, additional, Giorgino, T, additional, Guglielmelli, P, additional, Cazzola, M, additional, Maffioli, M, additional, Rambaldi, A, additional, Caramella, M, additional, Komrokji, R, additional, Gotlib, J, additional, Kiladjian, J J, additional, Cervantes, F, additional, Devos, T, additional, Palandri, F, additional, De Stefano, V, additional, Ruggeri, M, additional, Silver, R, additional, Benevolo, G, additional, Albano, F, additional, Caramazza, D, additional, Rumi, E, additional, Merli, M, additional, Pietra, D, additional, Casalone, R, additional, Barbui, T, additional, Pieri, L, additional, and Vannucchi, A M, additional

Published
2016
Full Text
View/download PDF

46. Theory Building Through Replication. Response to Commentaries on the Many Labs Replication Project

Author

Klein, R. A., Ratliff, K. A., Vianello, Michelangelo, Adams, R. B., J. r., Bahník, Š., Bernstein, M. J., Bocian, K., Brandt, M. J., Brooks, B., Brumbaugh, C. C., Cemalcilar, Z., Chandler, J., Cheong, W., Davis, W. E., Devos, T., Eisner, M., Frankowska, N., Furrow, D., Galliani, ELISA MARIA, Hasselman, F., Hicks, J. A., Hovermale, J. F., Hunt, S. J., Huntsinger, J. R., Ijzerman, H., John, M., Joy Gaba, J. A., Kappes, H. B., Krueger, L. E., Kurtz, J., Levitan, C. A., Mallett, R., Morris, W. L., Nelson, A. J., Nier, J. A., Packard, G., Pilati, R., Rutchick, A. M., Schmidt, K., Skorinko, J. L., Smith, R., Steiner, T. G., Storbeck, J., Vanswol, L. M., Thompson, D., van’t Veer, A., Vaughn, L. A., Vranka, M., Wichman, A., Woodzicka, J. A., and Nosek, B. A.

Subjects
Commentary, Replication, Iterative design
Published
2014

47. Robustness analysis of position observers for permanent magnet synchronous motors vis-à-vis rotor saliency

Author

Hernadez, M., Devos, T., Pillai, H., Ortega, Roméo, Malrait, F., Laboratoire des signaux et systèmes (L2S), and Université Paris-Sud - Paris 11 (UP11)-CentraleSupélec-Centre National de la Recherche Scientifique (CNRS)

Subjects
[INFO.INFO-AU]Computer Science [cs]/Automatic Control Engineering, [SPI.AUTO]Engineering Sciences [physics]/Automatic
Abstract

International audience; A gradient descentbased nonlinear observer for surfacemount permanent magnet synchronous motors (PMSMs) with remarkable stability properties was recently proposed in [7]. A key assumption for the derivation of the observer is the absence of rotor saliency, which is the case in surfacemount PMSMs. Practically, PMSMs have saliencies from low level for surfacemount PMSMs to high level for internalmount PMSMs. A question of great practical interest is to firstly assess the performance of the observer in the presence of saliency, and secondly to propose way of enhancement to take this effect into account. This is the topic of study of the present paper. We show in simulation the performance of the different observers.

Published
2013
Full Text
View/download PDF

49. Screening of JAK2 V617F and MPL W515 K/L negative essential thrombocythaemia patients for mutations in SESN2, DNAJC17, ST13, TOP1MT, and NTRK1

Author

UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service d'hématologie, Al Assaf, C., Lierman, E., Devos, T., Billiet, J., Graux, Carlos, Papadopoulos, P., Vandenberghe, P., UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service d'hématologie, Al Assaf, C., Lierman, E., Devos, T., Billiet, J., Graux, Carlos, Papadopoulos, P., and Vandenberghe, P.

Published
2014

50. Myelofibrosis patients in Belgium: disease characteristics

Author

Devos, T., primary, Zachée, P., additional, Bron, D., additional, Noens, L., additional, Droogenbroeck, J. Van, additional, Mineur, P., additional, Beguin, Y., additional, Berneman, Z., additional, Benghiat, F. S., additional, Kentos, A., additional, Chatelain, C., additional, Demuynck, H., additional, Lemmens, J., additional, Eygen, K. Van, additional, Theunissen, K., additional, Trullemans, F., additional, Pierre, P., additional, Pluymers, W., additional, and Knoops, L., additional

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results